
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion is a clinical-stage TechBio company with a promising platform, AI-Immunology, that utilizes artificial intelligence to develop novel vaccines for cancer and infectious diseases. The company's clinical pipeline is strong, with its lead personalized neoantigen vaccine, EVX-01, showing impressive efficacy and 86% immunogenicity in phase 2 trials. With a CEO known for engineering credible transactions and a strong balance sheet, Evaxion is well-positioned to capitalize on any potential business development opportunities in 2026, making it a promising investment option for the future.
Bears say
Evaxion is facing significant financial challenges due to its high operational burn rate of $14.0M coupled with minimal revenue generation of $7.5M in FY25, resulting in a net loss of $0.20 per diluted share. Furthermore, the preclinical stage of Evaxion's pipeline and absence of any approved products poses a high risk for investors, making the stock unattractive. Despite raising $30M in gross proceeds in 2025, Evaxion's current financial status and lack of near-term catalysts does not provide a positive outlook for the company's stock in the near future.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares